Search
forLearn
5 / 801 resultslearn HYDROXYPROPYLAMMONIUM GLUCONATE
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn panthenyl ethyl ether
Research
5 / 1000+ resultsresearch Effect of Pumpkin Seed Oil for the Treatment of Androgenetic Alopecia: Formulation and In-Vitro Evaluation
The F3 pumpkin seed oil gel showed excellent properties and better drug release for hair loss treatment.
research Formulation Development and In-Vitro Evaluation of Glycerosomes Containing Mionoxidil for Topical Application
The developed glycerosome gel improves minoxidil delivery for better alopecia treatment.
research Effect of Hydroxypropyl Methylcellulose (HPMC) in Release Profile of Air Fresheners Gel Prepared Using Carrageenan and HPMC
The F2 Emulgel with Tridax procumbens extract showed good physical properties and antimicrobial effectiveness for wound healing.
research FORMULATION AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FINASTERIDE
The F9 formulation of Finasteride tablets, using Eudragit, successfully controlled drug release.
research Formulation and Evaluation of Emulgel Containing Tridax Procumbens Extract
The F2 Emulgel with Tridax procumbens extract showed the best qualities for healing wounds.
Community Join
5 / 1000+ resultscommunity Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community POV: You Ask A Tressless User If It's Safe To Drink Minoxidil
This conversation is about how topical treatments for hair loss, such as Minoxidil and Finasteride, can be replaced by drinking oral versions of the same medications to achieve better results with less hassle. Some users have already been doing this with positive results.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.